Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787790 | 1.00 | MEN1 (0.41) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL1788531 | 0.84 | MEN1 (0.42) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL30814174 | 0.82 | MEN1 (0.45) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL1789193 | 0.82 | MEN1 (0.45) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL30795462 | 0.81 | POLB (0.46) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL1789475 | 0.81 | POLB (0.46) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL1787049 | 0.81 | MEN1 (0.40) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL30796204 | 0.81 | MEN1 (0.40) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL1786189 | 0.80 | POLB (0.41) | MEN1KMT2AMAPTLMNAPOLB | |
| SCHEMBL1791098 | 0.79 | ALDH1A1 (0.45) | MEN1KMT2ALMNAPOLBAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |